FK1706, is a host-targeted oral FKBP ligand that is synergistic in-vitro in combination with remdesivir inhibiting SARS-CoV-2 replication.
Tutela is seeking a partner to advance FK1706 in vivo studies.
https://www.biorxiv.org/content/10.1101/2022.02.03.479080v2
